For further details see:
Arcturus Therapeutics Q1 2022 Earnings PreviewFor further details see:
Arcturus Therapeutics Q1 2022 Earnings PreviewMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...